CONCLUSION
This study adds to the growing body of evidence that PPIs do not prevent
preeclampsia, despite their ability to reduce the secretion of sFlt-1.
Furthermore, calcium-based antacids did not reduce the risk of
preeclampsia in this population of pregnant women, even in high doses.
Based on these results, choice of treatment of symptoms of
gastroesophageal reflux does not need to be influenced by potential
beneficial side effects with regard to the risk of preeclampsia.
Nevertheless, benefit-risk assessment should also include other relevant
outcomes for maternal and child health, which slightly favour the choice
of calcium-based antacids.53 Future research may focus
on identifying specific groups of women for whom calcium-based antacids
or PPIs might reduce the risk of preeclampsia, in particular early-onset
preeclampsia.